60th Year Celebration of PK Deficiency as a Genetic Anemia Conference, 2022
Thrive with Pyruvate Kinase Deficiency is honored to have the following sponsors. We could not have hosted this wonderful event without their help!
TIF’s vision is to ensure equal access to quality health care for every patient with thalassaemia and other haemoglobin disorders across the world.
Agios is a biopharmaceutical company and leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. Our first genetically defined disease therapy was approved by the FDA for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Rocket Pharma’s mission is to develop first-in-class and best-in-class, curative gene therapies for patients with devastating diseases. Our vision is “Seeking Gene Therapy Cures”. Our company values of Trust, Be Generous, Be Curious and Elevate are at the heart of all that we do.
For information on a sponsorship package, please visit Sponsor Info
Please contact us with any questions you may have. We will be updating this website regularly.